Certain content on our website is available on for healthcare providers. Please confirm if you are an HCP to view full site content.

About Interfyl®

Follow Healing Wherever it Takes You

Support tissue regeneration wherever it’s needed with Interfyl.

Interfyl is suited for a variety of surgical applications when there is a need to replace or supplement damaged or inadequate integumental tissue.

Interfyl Is Connective Tissue Matrix (CTM)

The CTM used in Interfyl is derived from the placenta of a healthy, full-term pregnancy. It is a highly adaptable substance used by surgeons and wound care specialists to fill irregular spaces or soft tissue deficits resulting from wounds, trauma, or surgery.

  • Interfyl allows for cell adherence and growth during tissue repair, supplementing or replacing inadequate or damaged integumental tissue
  • Interfyl material is minimally manipulated and retains the fundamental structure and functional characteristics of connective tissue
The CTM used in Interfyl is derived from the placenta of a healthy full-term pregnancy

See Interfyl Healing in Action

Watch a brief video animation that illustrates the mechanism of action of Interfyl.

Interfyl is CTM derived from the chorion layer of the placenta

Interfyl is CTM derived from the chorion layer of the placenta that retains all the properties of connective tissue.

Interfyl Is Unique

Interfyl is unique because it is the only flowable human connective tissue matrix that does not contain amnion.

  • Interfyl is derived solely from the chorion layer of the placenta and provides structural support while still maintaining the natural elastic properties of the CTM. Because of these dual properties, Interfyl can be used in a myriad of medical, surgical, and tissue deficit situations.

Interfyl Offers Flexibility

Interfyl is available in two formulations that can be used across a variety of surgical and wound applications, including:

  • Replacement or supplementation of damaged or inadequate integumental tissue
  • Treatment of soft tissue voids, including:
    • Correction of soft tissue deficits
    • Soft tissue augmentation during repair of dehisced or complicated surgical closes
  • Repair of small surgical defects, including those with exposed vital structures such as bone, tendon, ligament, or nerve
  • Treatment of deep dermal wounds, surgical wounds, and soft tissue voids that are the result of:
    • Tunneling wounds
    • Fistula tracts
  • Dermal undermining (including those with exposed vital structures such as bone, tendon, ligament, or nerve)

Interfyl Is Easy to Use

Easy to prepare

  • Interfyl flowable is reconstituted with sterile saline or other sterile nonviscous fluid
    • Adding 0.3 mL-0.4 mL liquid (for 40 mg flowable) or 1.5 mL liquid (for 1.5 mL flowable) will achieve a toothpaste-like consistency
    • Based on preference or clinical application, consistency can be altered by adding more or less liquid
  • Particulate Interfyl may be used dry or wet
    • Product may be used “dry” by tapping or sprinkling the contents
    • Sterile saline or other sterile fluid may be added for a wet application
    • Consistency can be altered by adding more or less liquid

Convenient storage

  • Ambient room-temperature storage in a clean, dry environment – No refrigeration necessary
  • 5-year shelf life – Eliminates the need for preordering

Immunologically Inert Tissue

Interfyl has been minimally processed to maximize its natural benefits and safety.

  • Interfyl contains only natural human structural and biochemical extracellular matrix components

Additional safety features

Tissue used in processing Interfyl:

  • Has been procured, processed, and tested in accordance with standards established by the American Association of Blood Banks (AABB) and the United States Food and Drug Administration (FDA)
  • Passed safety testing for cytotoxicity, hemolysis, irritation, endotoxins, and pyrogenicity
  • Utilizes a barcode tracking system for optimal safety monitoring and to enhance patient and practitioner confidence
Interfyl is available in both flowable and particulate forms

Interfyl is available in both flowable and particulate forms.

  • 1.5 mL flowable in 3-mL syringe
  • 50 mg particulate in vial
  • 100 mg particulate in vial

Clinical Outcomes Gallery

Interfyl used in removal of failed hardware with excisional tissue transfer closure

Case characteristics:

  • 87-year-old female presented with diabetic foot ulcer following transmetatarsal amputation
  • Initial treatment included preparation of wound bed, including decrease of bioburden, debridement, and offloading
  • Performed excisional debridement of ulcer/bone and layered closure using Interfyl flowable to fill void
  • Despite patient noncompliance with post-op instructions and follow-up appointments, mature closure with viable tissue achieved 9 months post-op
Photo of open wound following transmetatarsal amputation

Day 1:
Open wound following transmetatarsal amputation

Photo of closed wound after 12 treatments with Interfyl

Day 270:
Mature closure 9 months from initial deep sterile abscess I&D with excisional debridement and layered closure and implantation of flowable Interfyl

Interfyl used in high-risk diabetic neuropathic ulcer with soft tissue loss and void

Case characteristics:

  • 70-year-old female presented with tunneling ulcer through medial to plantar to lateral hallux with tendon exposed
  • Initial treatment included oral levofloxacin 30 days until culture negative for bacteria
  • Wound bed prepared with high-powered saline debridement tool to remove devitalized tissue and any epibolized edges followed by one application of Interfyl flowable to fill void
  • Full mature closure achieved within 2 months and final discharge with full maturing at 4 months
Photo of tunneling plantar hallux ulcer on right big toe

Prior to Interfyl Implantation
High-risk tunneling plantar ulcer prepared for Interfyl following 2 negative cultures

Photo of closed wound 4 months after Interfyl implant

4 Months Post-Implant of Interfyl
Time to full mature closure noted within 2 months of one Interfyl implantation; final discharge with full maturation at 4 months

Interfyl used in high-risk diabetic neuropathic ulcer with soft tissue loss and void/irregular anatomical space in need of tissue structure support

Case characteristics:

  • 54-year-old male presented with chronic plantar foot ulcer (>1 year) resulting from diabetic neuropathy
  • Initial treatment included preparation of wound bed
  • Treatment included partial sesamoidectomy followed by 3 implantations using Interfyl flowable
  • Mature closure achieved at 122 days; growth flexor tendon remained viable and functional. Tissue remained viable with minimal scarring
Photo of open wound following partial sesamoidectomy

Day 1:
Prior to Interfyl implantations

Photo of closed wound

Day 122:
Mature closure following 3 implantations of Interfyl flowable

Connect With Celularity

For product questions, or ordering information, please contact us at customerservice@celularity.com or call us at 1-844-963-2273.

For medical inquiries, please contact us at medicalaffairs@celularity.com